Sun Pharma to Acquire Organon in US$11.75 Billion Deal

Sun Pharmaceutical Industries Ltd. has announced the acquisition of Organon in a landmark US$11.75 billion transaction, marking one of the largest deals in the global pharmaceutical industry.

The acquisition represents a major strategic milestone for Sun Pharma as it seeks to expand its global healthcare footprint, diversify its product portfolio, and strengthen its presence across key international markets. By combining Organon’s established portfolio with Sun Pharma’s existing capabilities, the company aims to create greater value for patients, healthcare providers, and shareholders worldwide.

Organon brings a broad portfolio spanning women’s health, biosimilars, and established medicines, along with a strong commercial presence across multiple global markets. The integration is expected to enhance Sun Pharma’s ability to deliver innovative and accessible healthcare solutions while expanding its reach into new therapeutic areas.

The transaction also reinforces Sun Pharma’s long-term growth strategy, focusing on global expansion, operational synergies, and innovation-driven healthcare. Following the acquisition, the combined entity is expected to benefit from a broader product pipeline, stronger research capabilities, and an enhanced global distribution network.

With this strategic move, Sun Pharma further cements its position among the world’s leading pharmaceutical companies, underscoring its commitment to advancing healthcare through innovation, scale, and expanded global access to medicines.